Ijpsr (2009), Issue 1, Vol

CONFLICTS OF INTEREST: Authors declare that there is no potential conflict of interest.

REFERENCES:

1. 
   http://www.cancer.gov/about-cancer/what-is-cancer.
   

updated: Aug 11, 2019

2. 
   Morris H: The Bradshaw Lecture on cancer and its origin; Delivered at the Royal College of Surgeons on December 9^th. Br Med J 1903; 2: 1505-11.
   
3. 
   Sitki-Copur M: State of cancer Research around the globe. Oncology Journal 2019; 33(5): 181-5.
   
4. 
   Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386.
   
5. 
   Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Can J Clin 2018; 68: 394-24.
   
6. 
   http://gicr.iarc.fr. Accessed April 23, 2019.
   
7. 
   Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S and Charlson FJ: Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053): 1659-24.
   
8. 
   Plummer M, de Martel C, Vignat J, Ferlay J, Bray F and Franceschi S: Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health 2016; 4(9): e609-16.
   
9. 
   Redmond DE: Tobacco and cancer: the first clinical report. 1761. N Engl J Med 1970; 282: 18-23.
   
10. 
    Burnham JC: American physicians and tobacco use: two Surgeons General, 1929 and 1964. Bull Hist Med 1989;
    

63: 1-31.

11. 
    Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 2000; 100: 57-70.
    
12. 
    Leitch A: A British Medical Association Lecture on the experimental inquiry into the causes of cancer. Br Med J 1923; 2: 1-7.
    
13. 
    Blackadar CB: Historical review of the cause of cancer. World J Clin Oncol 2016; 7(1): 54-86.
    
14. 
    http://www.cancer.gov/about-cancer/typesofcancer.
    
15. 
    www.cancerresearchuk.org updated: July 19, 2019
    
16. 
    Stewart BW and Wild CP: World cancer report 2014 Lyon: International Agency for Research on Cancer 2014.
    
17. 
    Lyon, France: International cancer community welcomes Global Initiative for Cancer Registry Development in Low- and Middle-Income Countries. International Agency for Research on Cancer 2011 November 18.
    
18. 
    Siegel R, Naishadham D and Jemal A: Cancer statistics. CA Cancer J Clin 2013; 63: 11-30.
    
19. 
    http://www.cancer.gov/about- cancer/symptomsandsignofcancer.
    
20. 
    www.moyoclinic.org.updated: July 07, 2019
    

21. 
    http://www.cancer.gov/about-cancer/diagnosis.
    
22. 
    Chakroborty S and Rahman T: The difficulties in cancer treatment. Ecancer Medical Science 2012; 6^th: 16.
    
23. 
    Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina- Pinelo S and Paz-Ares L: Current challenges in cancer treatments. Clinical Therapeutics 2016; 7: 1551-66.
    
24. 
    Raaijmakers MH, de Grouw EP, Heuver LH, van der Reijden BA, Jansen JH, Scheper RJ, Scheffer GL, de Witte TJ and Raymakers RA: Breast cancer resistance protein in drug resistance of primitive CD34+38- cells in acute myeloid leukemia. Clin Cancer Res 2005; 11: 2436-44.
    
25. 
    Celaya MO, Berke EM and Onega TL: Breast cancer stage at diagnosis and geographic access to mammography screening (New Hampshire, 1998-2004). Rural Remote Health 2010; 10: 1361-72.
    
26. 
    http://www.cancer.gov/about- cancer/typesofcancertreatments.
    
27. 
    Guidry JJ, Aday LA and Zhang D: Transportation as a barrier to cancer treatment. Can Pract 1997; 5: 361-66.
    
28. 
    Stitzenberg KB, Sigurdson ER, Egleston BL, Starkey RB and Meropol NJ: Centralization of cancer surgery: Implications for patient access to optimal care. J Clin Oncol 2009; 27: 4671-78.
    
29. 
    Delaney G, Jacob S, Feathtstone C and Barton M: The role of radiotherapy in cancer treatment. Cancer 2005; 104(6): 1129-37.
    
30. 
    Formenti SC and Demaria S: Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift. JNCI J Natl Cancer Inst 2013; 105: 256-65.
    
31. 
    Boeckman HJ: Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of non-homologous End Joining. Mol Cancer Res 2005; 3: 277-85.
    
32. 
    Harrison L, Hatahet Z and Wallace SS: In-vitro repair of synthetic ionizing radiation-induced multiply damaged DNA sites. J Mol Biol 1999; 290: 667-84.
    
33. 
    Luqmani YA: Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005; 14: 35-48.
    
34. 
    Einhorn, LH: First-line chemotherapy for non–small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 2008; 26: 3485-86.
    
35. 
    Zhang Q, Shi S, Yen Y, Brown J, Ta JQ and Le AD: A subpopulation of CD 133(+) cancer stem like cells charac- terized in human oral squamous cell carcinoma confer resistance to chemotherapy. Can Lett 2010; 289: 151-60.
    
36. 
    Klener P, Otahal P, Lateckova L and Klener P: Immunotherapy approaches in cancer treatment. Current Pharmaceutical Biotechnology 2015; 16(9): 771-81.
    
37. 
    Ventola CL: Cancer immunotherapy, part 3: challenges and future trends. P & T 2017; 42(8): 514-21.
    
38. 
    Ventola CL: Cancer immunotherapy, part1: current strategies and agents. P & T 2017; 42(6): 375-83.
    
39. 
    Pardoll D: Cancer and the immune system: basic concepts & targets for intervention. Sem in On 2015; 42(4): 523-38.
    
40. 
    He Q, Liu Z, Lai Y, Zhou X and Weng J: TCR-like antibodies in cancer immunotherapy. J Hematol Oncol 2019; 12(1): 99.
    
41. 
    Michel L, Rassaf T and Totzeck M: Cardiotoxicity from immune checkpoint inhibitors. Int J Cardiol Heart Vasc 2019; 25: 100420.
    
42. 
    Liauw WS: Molecular mechanisms and clinical use of targeted anticancer drugs. Aust Presc 2013; 36(4): 126-11.
    
43. 
    www.cancer.gov/cancertopics/factsheet/Theraphy.
    
44. 
    Yin Z, Bai L, Li W, Zeng T, Tian H and Cui J: Targeting T cell metabolism in the tumor microenvironment: an anticancer therapeutic strategy. J Exp Clin Cancer Res 2019; 38(1): 403.
    
45. 
    https://www.cancercenter.com/treatment- options/chemotherapy/hormone-therapy.
    
46. 
    http://www.washingtonpost.com/wpdyn/content/article/20 10/10/19/AR2010101907522.html
    
47. 
    Shook LL: An update on Hormone Replacement Therapy. Yale J Biol Med 2011; 84(1): 39-42.
    
48. 
    https://www.cancer.gov/about- cancer/treatment/types/hormone-therapy
    
49. 
    Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF and Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 1(4): 973-78.
    
50. 
    Seo DC, Sung JM, Cho HJ, Yi H, Seo KH, Choi IS, Kim DK, Kim JS, Abd El-Aty AM and Shin HC: Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 2007; 107-09.
    
51. 
    Mimeault M, Hauke R, Mehta PP and Batra SK: Recent advances in cancer stem/progenitor cell research: thera- peutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 2007; 11: 981-11.
    
52. 
    Wicha MS, Liu S and Dontu G: Cancer stem cells: an old idea – a paradigm shift. Cancer Res 2006; 66: 1883-890.
    
53. 
    Harper LJ, Piper K, Common J, Fortune F and Mackenzie IC: Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007; 36: 594-03.
    
54. 
    Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD and Sorrentino BP: Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in-vivo. Proceedings of the National Academy of Sciences 2002; 99(19): 12339-44.
    
55. 
    Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-11.
    
56. 
    Kelly PN, Dakic A, Adams JM, Nutt SL and Strasser A: Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317(5836): 337.
    
57. 
    Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5(4): 275-84.
    
58. 
    Polyak K: Breast cancer stem cells: a case of mistaken identity? Stem Cell Rev 2007; 3: 107-09.
    
59. 
    Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard JY, Eggermont A, Eniu A, McGregor K, Peters S, Piccart M, Popescu R, Cutsem EV, Zielinski C and Stahel R: Delivering precision medicine in osncology today and in future-the promise and challenges of personalized cancer medicine: Aposition paper by the European Society for Medical Oncology (ESMO). Ann Onco 2014; 25: 1673-78.
    
60. 
    Walko CM and McLeod HL: Personalizing medicine in geriatric oncology. J Clin Oncol 2014; 32: 2581-86.
    

How to cite this article:
Saini A, Kumar M, Bhatt S, Saini V and Malik A: Cancer causes and treatments. Int J Pharm Sci & Res 2020; 11(7): 3121-34. doi: 10.13040/IJPSR.0975-8232.11(7).3121-34.

All © 2013 are reserved by the International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
This article can be downloaded to ANDROID OS based mobile. Scan QR Code using Code/Bar Scanner from your mobile. (Scanners are available on Google Playstore)